journal
MENU ▼
Read by QxMD icon Read
search

Breast: Official Journal of the European Society of Mastology

journal
https://www.readbyqxmd.com/read/28806663/management-of-breast-ductal-carcinoma-in-situ-in-catalonia-spain-results-from-the-grup-oncologic-calal%C3%A3-occit%C3%A3-catalonia-survey-with-9-year-follow-up
#1
M J Cambra, B Farrús, F Moreno, Ll Anglada, M Arenas, R Ballester, J Casals, M Cusidó, V García, C Gutiérrez, M Mollà, A Pedro, V Reyes, X Sanz
INTRODUCTION: Reliable data on DCIS incidence and management are not available in many countries. The present study describes the management of DCIS in Catalonia, Spain in the year 2005 and compares these findings to data obtained in France. Local recurrence and late toxicity rates from 2005 through the end of 2014 are reported. MATERIALS AND METHODS: Observational survey of patients with pure DCIS (n = 270) diagnosed during 2005. A written questionnaire, the same as used in the French survey, was completed by 14 doctors at 12 cancer centres in Catalonia, Spain...
August 11, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28800545/liver-toxicity-of-chemotherapy-and-targeted-therapy-for-breast-cancer-patients-with-hepatitis-virus-infection
#2
Yu Liu, Zhan-Yi Li, Xi Li, Jia-Ni Wang, Qun-Ai Huang, Yong Huang
BACKGROUND: Chemotherapy has greatly improved the prognosis of breast cancer patients. However, it may also result in undesirable side effects such as hepatitis virus reactivation. Little information is available on the liver toxicity of chemotherapy and targeted therapy for breast cancer patients with hepatitis virus (HBV/HCV) infection. METHODS: We performed a retrospective survey of 835 patients diagnosed with breast cancer between January 2010 and December 2015 at our institution...
August 8, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28781102/omitting-radiation-therapy-after-lumpectomy-for-pure-dcis-does-not-reduce-the-risk-of-salvage-mastectomy
#3
Eileen Rakovitch, Sharon Nofech-Mozes, Wedad Hanna, Rinku Sutradhar, Sumei Gu, Cindy Fong, Alan Tuck, Bruce Youngson, Naomi Miller, Susan J Done, Martin C Chang, Sandip Sengupta, Leela Elavathil, Prashant A Jani, Michel Bonin, Nafisha Lalani, Lawrence Paszat
PURPOSE: Radiation therapy (RT) after breast-conserving surgery (BCS) for Ductal Carcinoma in Situ (DCIS) halves the risk of local recurrence (LR). The omission of RT is often supported by the paradigm that patients who develop LR can be salvaged with further breast-conserving therapy leading to higher rates of breast preservation and improved quality of life. However, population-based, long-term rates of breast preservation in women treated by upfront BCS ± RT are unknown. METHODS AND MATERIALS: Women diagnosed with pure DCIS from 1994 to 2003 treated with BCS ± RT in Ontario were identified...
August 3, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28774554/re-secondary-gastric-cancer-following-a-breast-cancer-diagnosis-beware-of-metastatic-breast-cancer
#4
LETTER
Alyson L Mahar, Daniel J Kagedan, Julie Hallet, Natalie G Coburn
No abstract text is available yet for this article.
July 31, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28768227/variation-in-the-provision-and-practice-of-implant-based-breast-reconstruction-in-the-uk-results-from-the-ibra-national-practice-questionnaire
#5
Senthurun Mylvaganam, Elizabeth Conroy, Paula R Williamson, Nicola L P Barnes, Ramsey I Cutress, Matthew D Gardiner, Abhilash Jain, Joanna M Skillman, Steven Thrush, Lisa J Whisker, Jane M Blazeby, Shelley Potter, Christopher Holcombe
INTRODUCTION: The introduction of biological and synthetic meshes has revolutionised the practice of implant-based breast reconstruction (IBBR) but evidence for effectiveness is lacking. The iBRA (implant Breast Reconstruction evAluation) study is a national trainee-led project that aims to explore the practice and outcomes of IBBR to inform the design of a future trial. We report the results of the iBRA National Practice Questionnaire (NPQ) which aimed to comprehensively describe the provision and practice of IBBR across the UK...
July 30, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28756339/whole-body-mri-for-systemic-staging-of-breast-cancer-in-pregnant-women
#6
Fedro A Peccatori, Giovanni Codacci-Pisanelli, Maria Del Grande, Giovanna Scarfone, Fabio Zugni, Giuseppe Petralia
When breast cancer is diagnosed during pregnancy, treatment should be as close; as possible to what is used in non-pregnant patients. This requires accurate local and systemic staging: ultrasound (US) is used for local staging and allows adequate evaluation of the liver and pelvis, but chest and bones cannot be explored and imaging techniques involving exposure to ionizing radiation would be needed. However, since imaging techniques involving ionizing radiation and the use of radionuclides should be limited, whole body magnetic resonance imaging (WB-MRI) without administration of contrast agent represents a very interesting alternative, but limited data is available...
July 27, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28756338/patterns-of-care-for-ductal-carcinoma-in-situ-of-the-breast-queensland-s-experience-over-a-decade
#7
Samantha Barbour, Julie Moore, Nathan Dunn, Rachel Effeney, Hazel Harden, Alexandra McCarthy, Euan Walpole, Margot Lehman
OBJECTIVES: To review management of ductal carcinoma in situ (DCIS) of the breast in Queensland, with reference to breast conserving surgery (BCS) and adjuvant radiation therapy (RT). In addition, we examined the incidence of invasive breast cancer recurrence and factors predictive of invasive recurrence. MATERIALS AND METHODS: A retrospective review of the Queensland Oncology Repository identified women with resected DCIS (TisN0) ± adjuvant RT between 2003 and 2012...
July 27, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28755621/prognostic-assessment-and-systemic-treatments-of-invasive-local-relapses-of-hormone-receptor-positive-breast-cancer
#8
REVIEW
Anna Zingarello, Chafika Mazouni, Sofia Rivera, Meriem Mokdad-Adi, Barbara Pistilli
The rate of local recurrences, after breast-conserving surgery or mastectomy for hormone receptor-positive (HR+) breast cancer, has dramatically changed in last decades, due to advances in surgical and radiation techniques and a more extensive use of adjuvant systemic treatments. However, the occurrence of local recurrences remains a major predictor for distant metastasis and is responsible for increased cancer-specific death. It has been estimated that 1 in 4 HR+ and HR-ipsilateral breast recurrences leads to widespread metastatic disease, with an annual mortality rate of 10% in the first 5 years...
July 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28753473/reduction-mammaplasty-in-patients-with-history-of-breast-cancer-the-incidence-of-occult-cancer-and-high-risk-lesions
#9
Päivi A Merkkola-von Schantz, Tiina A Jahkola, Leena A Krogerus, Susanna M C Kauhanen
INTRODUCTION: Contralateral reduction mammaplasty is regularly included in the treatment of breast cancer patients. We analyzed the incidence of occult breast cancer and high-risk lesions in reduction mammaplasty specimens of women with previous breast cancer. We also analyzed if timing of reduction mammaplasty in relation to oncological treatment influenced the incidence of abnormal findings, and compared if patients with abnormal contralateral histopathology differed from the study population in terms of demographics...
July 25, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28743035/current-trials-to-reduce-surgical-intervention-in-ductal-carcinoma-in-situ-of-the-breast-critical-review
#10
REVIEW
M Toss, I Miligy, A M Thompson, H Khout, A R Green, I O Ellis, E A Rakha
The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening and the relatively low risk of progression to invasive disease have raised questions related to overtreatment. Following a review of current DCIS management protocols a more conservative approach has been suggested. Clinical trials have been introduced to evaluate the option of avoiding surgical intervention in a proportion of patients with DCIS defined as "low-risk" using certain clinicopathological criteria. These trials can potentially provide evidence-based models of active surveillance (with or without endocrine therapy) as a future management approach...
July 22, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28735162/tumor-infiltrating-lymphocytes-in-breast-cancer-according-to-tumor-subtype-current-state-of-the-art
#11
REVIEW
Cinzia Solinas, Luisa Carbognin, Pushpamali De Silva, Carmen Criscitiello, Matteo Lambertini
The recent success of the immune checkpoint blockade in cancer immunotherapy has modified the treatment algorithms in a variety of aggressive neoplastic diseases. Nevertheless, optimal selection of ideal candidates to these drugs remains a challenge. The presence, location and composition of a pre-existing tumor immune infiltrate seem to impact on the benefit from these treatments. The association between the presence of baseline tumor-infiltrating lymphocytes (TIL) and patients' outcomes has been widely investigated in breast cancer, although immunotherapeutic strategies have historically been less successful with respect to other neoplastic diseases such as melanoma and kidney cancer...
July 20, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28734762/breast-cancer-mortality-in-european-union-an-outlook-of-good-news-and-bad-news-in-a-two-speed-europe
#12
EDITORIAL
Giuseppe Curigliano, Fatima Cardoso
No abstract text is available yet for this article.
July 19, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28732325/epidemiology-and-pathophysiology-of-pregnancy-associated-breast-cancer-a-review
#13
REVIEW
Rossana Ruiz, Carmen Herrero, Kathrin Strasser-Weippl, Diego Touya, Jessica St Louis, Alexandra Bukowski, Paul E Goss
The interactions between pregnancy and breast cancer (BC) are complex. Overall, parity is associated with long-term protective effects against BC, however in a small group of susceptible patients, pregnancy can lead to the development of a form of BC with a particularly poor prognosis. Pregnancy-associated breast cancer (PABC) remains an under-studied but important and growing clinical problem worldwide. Several aspects of PABC, including risk factors and mechanisms involved in its occurrence and aggressiveness, are incompletely understood...
July 18, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28732324/anti-m%C3%A3-llerian-hormone-amh-levels-in-premenopausal-breast-cancer-patients-treated-with-taxane-based-adjuvant-chemotherapy-a-translational-research-project-of-the-success-a-study
#14
Elisabeth Trapp, J Steidl, B Rack, M S Kupka, U Andergassen, J Jückstock, A Kurt, T Vilsmaier, A de Gregorio, N de Gregorio, M Tzschaschel, C Lato, A Polasik, H Tesch, A Schneeweiss, M W Beckmann, P A Fasching, W Janni, V Müller
BACKGROUND: Premenopausal women undergoing chemotherapy are at high risk for premature ovarian failure and its long-term consequences. Data on potential markers to evaluate ovarian reserve pre- and posttreatment are limited. Anti-Müllerian hormone (AMH) known for ovarian reserve in reproductive medicine could be a surrogate marker and was assessed in premenopausal breast cancer patients of the SUCCESS A study (EUDRA-CT no. 2005-000490-21). METHODS: We identified 170 premenopausal patients, age ≤ 40 years at trial entry, who received FEC-Doc as taxane-anthracylince based chemotherapy...
July 18, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28719811/risk-of-secondary-malignancies-after-radiation-therapy-for-breast-cancer-comprehensive-results
#15
Lindsay M Burt, Jian Ying, Matthew M Poppe, Gita Suneja, David K Gaffney
GOALS: To assess risks of secondary malignancies in breast cancer patients who received radiation therapy compared to patients who did not. METHODS: The SEER database was used to identify females with a primary diagnosis of breast cancer as their first malignancy, during 1973-2008. We excluded patients with metastatic disease, age <18 years, no definitive surgical intervention, ipsilateral breast cancer recurrence, or who developed a secondary malignancy within 1 year of diagnosis...
July 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28711793/efficacy-and-safety-of-everolimus-and-exemestane-in-hormone-receptor-positive-hr-human-epidermal-growth-factor-negative-her2-advanced-breast-cancer-patients-new-insights-beyond-clinical-trials-the-eva-study
#16
M E Cazzaniga, M Airoldi, V Arcangeli, S Artale, F Atzori, A Ballerio, G V Bianchi, L Blasi, S Campidoglio, M Ciccarese, M C Cursano, M Piezzo, A Fabi, L Ferrari, A Ferzi, C Ficorella, A Frassoldati, A Fumagalli, O Garrone, V Gebbia, D Generali, N La Verde, M Maur, A Michelotti, G Moretti, A Musolino, R Palumbo, M Pistelli, M Porpiglia, D Sartori, C Scavelli, A Schirone, A Turletti, M R Valerio, P Vici, A Zambelli, L Clivio, V Torri
BACKGROUND: The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant...
July 13, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28709114/isolated-pachymeningeal-metastasis-from-breast-cancer-clinical-features-and-prognostic-factors
#17
Mi Hwa Heo, Yoo Jin Cho, Hee Kyung Kim, Ji-Yeon Kim, Yeon Hee Park
PURPOSE: To evaluate the clinical features and prognoses of patients with isolated pachymeningeal metastasis (IPM) from breast cancer. METHODS: We reviewed the medical records of all patients with metastatic breast cancer (MBC) treated from January 2009 to August 2016. Eligibility criteria included diagnosis of pachymeningeal metastasis based on brain magnetic resonance imaging and histologic diagnosis of primary breast cancer. We excluded patients with concomitant parenchymal or leptomeningeal metastases...
July 11, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28704698/interventional-radiology-in-breast-cancer
#18
REVIEW
Lizbeth Moira Kenny, Franco Orsi, Andreas Adam
Molecular profiling of metastatic disease may greatly influence the systemic therapy recommended by oncologists and chosen by patients, allowing treatment to be more targeted. Comprehensive care of patients with advanced breast cancer now includes percutaneous image-guided biopsy if this has the potential to influence systemic treatment [1]. Interventional radiologists can contribute significantly to the care of patients affected by breast cancer, in diagnostic and supportive procedures and importantly also in treatment...
July 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28704697/the-use-of-ultrasound-in-the-clinical-re-staging-of-the-axilla-after-neoadjuvant-chemotherapy-nact
#19
Anastasia Peppe, Robin Wilson, Romney Pope, Kate Downey, Jennifer Rusby
INTRODUCTION: Ultrasound (US) is the imaging modality of choice for staging the axilla prior to surgery in patients with breast cancer (BC). High pathological complete response rates in the axilla after NACT mean a more conservative approach to surgery can be considered. Radiological re-staging is important in this decision making. After the presentation of results from ACOSOG Z1071 in December 2012, formal ultrasound re-assessment of the axilla after primary therapy was specifically requested in our institution...
July 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28694015/predicting-treatment-resistance-and-relapse-through-circulating-dna
#20
Emma Beddowes, Stephen J Sammut, Meiling Gao, Carlos Caldas
The use of circulating DNA(ctDNA) to provide a non-invasive, personalised genomic snapshot of a patients' tumour has huge potential. Over the past five years this area of research has gained huge momentum. A number of studies in metastatic breast cancer have shown the potential of ctDNA to predict prognosis and treatment response using ctDNA. Further developments have included deeper sequencing using whole exome and shallow whole genome approaches which has the potential to identify new mutations and chromosomal copy number changes which appear upon resistance to treatment...
July 8, 2017: Breast: Official Journal of the European Society of Mastology
journal
journal
31139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"